额颞叶痴呆患者癫痫患病率及痴呆诊断时机
这项病例对照研究比较了芬兰两个早发型痴呆诊断中心中额颞叶痴呆(FTD)、匹配健康对照(HC)和阿尔茨海默病(AD)患者的癫痫患病率及抗癫痫药物(ASM)购买情况。结果显示,FTD患者从诊断前10年至诊断后5年癫痫患病率均高于HC,诊断时及诊断后5年也高于AD,ASM购买更频繁,提示癫痫异常与FTD病理生理相关。
要点
- FTD诊断前10年癫痫患病率已高于HC和AD。
- FTD诊断时癫痫患病率为6.5%,5年后升至11.2%。
- FTD患者ASM购买率10.2%,高于HC和AD。
核心结论
- FTD患者癫痫患病率及ASM使用率高于健康对照和AD患者,提示癫痫异常与FTD病理生理相关。
研究设计与样本
- 病例对照研究,纳入芬兰两个早发型痴呆诊断中心的245例FTD、2416例匹配HC和1326例AD患者。
- FTD和AD诊断时间为2010年1月1日至2021年12月31日,数据分析时间为2024年1月26日至2025年1月16日。
临床怎么用
- 对FTD患者应关注癫痫症状,诊断前后均可考虑评估癫痫并进行ASM管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Previous studies have described a potential association between epilepsy and frontotemporal dementia (FTD), but no systematic data are available. OBJECTIVE: To determine whether epilepsy is more prevalent in patients with FTD than in healthy controls (HCs) or patients with Alzheimer disease (AD). DESIGN, SETTING, AND PARTICIPANTS: In this case-control study, we compared the prevalence of epilepsy and purchases of antiseizure medicines (ASMs) among patients with FTD, matched HCs, and patients with AD from 2 early-onset dementia diagnostics centers in the same geographic regions of Finland. AD or FTD diagnoses were made between January 1, 2010, and December 31, 2021. Data were analyzed from January 26, 2024, to January 16, 2025. MAIN OUTCOMES AND MEASURES: The primary outcome was to describe the prevalence of epilepsy in patients with FTD, covering the time period from 10 years before to 5 years after the FTD diagnosis. We used International Statistical Classification of Diseases, Tenth Revision codes to identify all patients with epilepsy and tracked purchases of ASMs. RESULTS: The study cohort included 245 patients with FTD (121 female [49.4%], 124 male [50.6%]; mean [SD] age, 65.2 [8.7] years), 2416 matched HCs (1190 female [49.3%], 1226 male [50.7%]; mean [SD] age, 65.0 [8.5] years), and 1326 patients with AD (777 female [58.6%], 549 male [41.4%]; mean [SD] age, 71.7 [9.8] years). The prevalence of epilepsy was higher in the FTD group compared with the HC group (3.3% vs 0.8%, respectively; P = .002) and AD group (3.3% vs 1.4%, respectively; P = .01) 10 years before FTD diagnosis. At the year of the diagnosis, the prevalence was 6.5% in patients with FTD, 1.8% in HCs (FTD vs HC difference, 4.7 percentage points [ppt] [95% CI, 2.2-8.6 ppt]; P < .001), and 5.0% in patients with AD (FTD vs AD difference, 1.6 ppt [95% CI, -1.2 to 5.5 ppt]; P = .32); at 5 years after the diagnosis, the prevalence was 11.2% in patients with FTD, 2.2% in HCs (FTD vs HC difference, 9.0 ppt [95% CI, 5.0-14.6 ppt]; P < .001), and 6.9% in patients with AD (FTD vs AD difference, 4.2 ppt [95% CI, 0-10.0 ppt]; P = .05). ASM purchases were made significantly more often among patients with FTD (10.2%) compared with HCs (1.8%) and patients with AD (4.2%) (FTD vs HC difference, 8.4 ppt [95% CI, 5.2-12.9 ppt]; P < .001; FTD vs AD difference, 6.1 ppt [95% CI, 2.6-10.6 ppt]; P < .001) at all time points and increased during the study period. CONCLUSIONS AND RELEVANCE: This case-control study found a higher prevalence of epilepsy and increased ASM use among patients with FTD compared with HCs and patients with AD , suggesting an association between epileptic abnormalities and the pathophysiology of FTD. Further studies are warranted to investigate a potential overlap in the pathophysiologic mechanisms of epilepsy and FTD.
引用
- Kilpeläinen A, Aaltonen M, Aho K, et al. Prevalence of Epilepsy in Frontotemporal Dementia and Timing of Dementia Diagnosis. JAMA Neurol. 2025. PMID: 40455437. doi:10.1001/jamaneurol.2025.1358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。